Research ArticleOpen Access

Extended RAS Mutational Status Analysis in Circulating Tumor DNA from Patients with Advanced Colorectal Cancer in Daily Clinical Practice. The Franco-British Institute Experience and Recommendations

Volume 6 - Issue 5

Laurence Heuls¹, Nathalie Perez Staub², Ida Iurisci^1,2, Perrine Goyer³, Arnaud Saget⁴, Hubert Richa⁵, Hélène Marijon², Linda Dainese⁶, Annette K Larsen^7,8, Aimery De Gramont^1,2,7,8 and Benoist Chibaudel*^1,2,7,8

Author Information Open or Close
- ¹Department of Clinical and Translational Cancer Research Unit, Franco-British Institute, Levallois Perret, France
- ²Department of Medical Oncology, FrancoBritish Institute, Levallois Perret, France
- ³Department of Gastrointestinal Surgery, Clinique Turin, France
- ⁴Department of Gastrointestinal Surgery, Clinique Ambroise Paré, Neuilly SurSeine, France
- ⁵Department of Gastrointestinal Surgery, FrancoBritish Institute, Levallois Perret, France
- ⁶Department of Center of Anatomic Pathology, Institut De Pathologie De Paris, Malakoff, France
- ⁷Depatment of Cancer Biology and Therapeutics, Centre De Recherche Saint-Antoine (CRSA), France
- ⁸Institut National de la Santé et de la Recherche Médicale (INSERM) U938, Paris, France
*Corresponding author: Benoist Chibaudel, Department of Medical Oncology, Franco British Institute, France

Received: June 25, 2018; Published: July 13, 2018

DOI: 10.26717/BJSTR.2018.06.001409

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Background : The development of liquid biopsies could help clinicians to shorten treatment decision and allow longitudinal molecular monitoring. We report here our experience of using the Biocartis IdyllaTM test for patients with advanced colorectal cancer in daily clinical practice.

Patients and Methods: This program prospectively enrolled patients with advanced colorectalcancer at the Department of Medical Oncology of the Franco-British Institute, Levallois-Perret,France.Theprimary objective was to evaluate the feasibilty of the IdyllaTM testing in daily clinical practice.

Results: From November 17, 2017 to June 12,2018, 50 patients were tested. The median time to circulating tumor (ct) extended mutational status was 4.8 hours (95% CI:4.7-5.1). Among 37 (74.0%) patients with paired plasma and tumor samples available, the overall agreement rate was 73.0%. In patients with previously untreated metastatic liver disease (n=9;18%), the overall agreement rate between paired plasma and tumor samples was 100.0%, and the weighted K coefficient was 1.00 (95% CI: 1.00-1.00).

Conclusion : Extended RAS mutational status analysis in circulating tumor DNA from patients with advanced colorectal cancer is feasible and greatly helpful for daily clinical practice. We recommend restricting ctDNA testing with IdyllaTM to patients with previously untreated liver metastatic disease.

Keywords: Colorectal Cancer; Liquid Biopsy; KRAS; NRAS; BRAF

Abbreviations: EGF: Epidermal Growth Factor; MoAb: Monoclonal Antibodies; KRAS: Kirsten Rat Sarcoma Viral Oncogene Homolog; ECD: Extra Cellular Domain; ctDNA: Circulating Tumor DNA; CT: Circulating Tumor